A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990-2017.
Hematologic malignancies
Hodgkin lymphoma
Leukemia
Multiple myeloma
Non-hodgkin lymphoma
Quality of Care Index
Journal
Experimental hematology & oncology
ISSN: 2162-3619
Titre abrégé: Exp Hematol Oncol
Pays: England
ID NLM: 101590676
Informations de publication
Date de publication:
08 Feb 2021
08 Feb 2021
Historique:
received:
28
11
2020
accepted:
04
01
2021
entrez:
9
2
2021
pubmed:
10
2
2021
medline:
10
2
2021
Statut:
epublish
Résumé
Hematologic malignancies (HMs) are a heterogeneous group of cancers that comprise diverse subgroups of neoplasms. So far, despite the major epidemiologic concerns about the quality of care, limited data are available for patients with HMs. Thus, we created a novel measure-Quality of Care Index (QCI)-to appraise the quality of care in different populations. The Global Burden of Disease data from 1990 to 2017 applied in our study. We performed a principal component analysis on several secondary indices from the major primary indices, including incidence, prevalence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) to create the QCI, which provides an overall score of 0-100 of the quality of cancer care. We estimated the QCI for each age group on different scales and constructed the gender disparity ratio to evaluate the gender disparity of care in HMs. Globally, while the overall age-standardized incidence rate of HMs increased from 1990 to 2017, the age-standardized DALYs and death rates decreased during the same period. Across countries, in 2017, Iceland (100), New Zealand (100), Australia (99.9), and China (99.3) had the highest QCI scores for non-Hodgkin lymphoma, multiple myeloma, Hodgkin lymphoma, and leukemia. Conversely, Central African Republic (11.5 and 6.1), Eritrea (9.6), and Mongolia (5.4) had the lowest QCI scores for the mentioned malignancies respectively. Overall, the QCI score was positively associated with higher sociodemographic of nations, and was negatively associated with age advancing. The QCI provides a robust metric to evaluate the quality of care that empowers policymakers on their responsibility to allocate the resources effectively. We found that there is an association between development status and QCI and gender equity, indicating that instant policy attention is demanded to improve health-care access.
Sections du résumé
BACKGROUND
BACKGROUND
Hematologic malignancies (HMs) are a heterogeneous group of cancers that comprise diverse subgroups of neoplasms. So far, despite the major epidemiologic concerns about the quality of care, limited data are available for patients with HMs. Thus, we created a novel measure-Quality of Care Index (QCI)-to appraise the quality of care in different populations.
METHODS
METHODS
The Global Burden of Disease data from 1990 to 2017 applied in our study. We performed a principal component analysis on several secondary indices from the major primary indices, including incidence, prevalence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years (DALYs) to create the QCI, which provides an overall score of 0-100 of the quality of cancer care. We estimated the QCI for each age group on different scales and constructed the gender disparity ratio to evaluate the gender disparity of care in HMs.
RESULTS
RESULTS
Globally, while the overall age-standardized incidence rate of HMs increased from 1990 to 2017, the age-standardized DALYs and death rates decreased during the same period. Across countries, in 2017, Iceland (100), New Zealand (100), Australia (99.9), and China (99.3) had the highest QCI scores for non-Hodgkin lymphoma, multiple myeloma, Hodgkin lymphoma, and leukemia. Conversely, Central African Republic (11.5 and 6.1), Eritrea (9.6), and Mongolia (5.4) had the lowest QCI scores for the mentioned malignancies respectively. Overall, the QCI score was positively associated with higher sociodemographic of nations, and was negatively associated with age advancing.
CONCLUSIONS
CONCLUSIONS
The QCI provides a robust metric to evaluate the quality of care that empowers policymakers on their responsibility to allocate the resources effectively. We found that there is an association between development status and QCI and gender equity, indicating that instant policy attention is demanded to improve health-care access.
Identifiants
pubmed: 33557940
doi: 10.1186/s40164-021-00198-2
pii: 10.1186/s40164-021-00198-2
pmc: PMC7869509
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11Références
Soc Work Health Care. 2010;49(1):38-52
pubmed: 20077318
Chin J Cancer Res. 2017 Jun;29(3):253-262
pubmed: 28729776
Soc Sci Med. 2014 Sep;116:56-63
pubmed: 24980792
Epidemiol Health. 2017 Feb 5;39:e2017006
pubmed: 28171715
Acta Oncol. 2018 Apr;57(4):440-455
pubmed: 29226751
Mutat Res. 2006 Nov-Dec;613(2-3):138-60
pubmed: 17049456
Cancer. 2014 May 15;120(10):1572-8
pubmed: 24549743
J Clin Oncol. 2009 Jun 10;27(17):2881-5
pubmed: 19403885
Int J Cancer. 2011 Jul 15;129(2):467-75
pubmed: 21207370
Crit Rev Oncol Hematol. 2008 Aug;67(2):124-32
pubmed: 18375141
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Aging (Albany NY). 2020 Nov 16;12(22):22869-22891
pubmed: 33203796
Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S3-12
pubmed: 12734687
PLoS One. 2018 Jan 9;13(1):e0190298
pubmed: 29315325
JAMA. 2016 Oct 25;316(16):1643-1644
pubmed: 27668895
Exp Hematol Oncol. 2020 Jun 19;9:14
pubmed: 32577323
Nurs Womens Health. 2012 Oct-Nov;16(5):372-85
pubmed: 23067282
J Clin Invest. 2012 Oct;122(10):3456-63
pubmed: 23023717
J Hematol Oncol. 2020 Jun 8;13(1):72
pubmed: 32513227
Cancer Causes Control. 2007 Dec;18(10):1209-26
pubmed: 17874193
PLoS One. 2020 May 6;15(5):e0232848
pubmed: 32374771
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Br J Haematol. 2011 Sep;154(6):696-703
pubmed: 21707579
J Gastrointest Oncol. 2019 Jun;10(3):453-461
pubmed: 31183195
Blood. 2012 May 31;119(22):5078-87
pubmed: 22461494
Cancer Causes Control. 2008 Sep;19(7):711-23
pubmed: 18322816
Pan Afr Med J. 2016 Sep 21;25:18
pubmed: 28154710
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Ther Adv Hematol. 2013 Aug;4(4):270-90
pubmed: 23926459
J Hematol Oncol. 2019 Oct 22;12(1):107
pubmed: 31640759
Blood. 2017 Jul 27;130(4):410-423
pubmed: 28600336
Lancet. 2016 Dec 10;388(10062):e19-e23
pubmed: 27371184
Lancet HIV. 2019 Dec;6(12):e831-e859
pubmed: 31439534
Int J Gen Med. 2019 Nov 06;12:395-403
pubmed: 31819592
Glob Health Promot. 2015 Jun;22(2):31-9
pubmed: 25027971
Lancet. 2018 Jun 2;391(10136):2236-2271
pubmed: 29893224
J Clin Oncol. 2011 Oct 1;29(28):3816-24
pubmed: 21810680
Int J Environ Res Public Health. 2018 Dec 17;15(12):
pubmed: 30562951
Lancet Haematol. 2018 Jan;5(1):e14-e24
pubmed: 29304322
Lancet. 2018 Nov 10;392(10159):1859-1922
pubmed: 30415748
J Glob Oncol. 2015 Sep 23;1(1):30-36
pubmed: 28804769
Lancet Glob Health. 2018 May;6(5):e555-e567
pubmed: 29653628
Ann Oncol. 2007 Jan;18 Suppl 1:i3-i8
pubmed: 17311819
Br J Radiol. 1997 Feb;70:130-9
pubmed: 9135438
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Leuk Res. 2007 Mar;31(3):379-86
pubmed: 16919329
Health Policy. 2015 Sep;119(9):1145-52
pubmed: 26251322
N Engl J Med. 2015 Oct;373(14):1285-9
pubmed: 26422719
J Natl Cancer Inst. 2003 Nov 5;95(21):1615-23
pubmed: 14600094